provides general information regarding cytisine

Quit Smoking with Tabex
Sopharma Shop

Achieve Lifesciences has revealed that the Phase 2b trial planned for the fourth quarter will evaluate 1.5 mg and 3 mg cytisine dosing on a declining titration dose over a period of 25 days. Additionally, the company plans to evaluate 1.5 mg and 3 mg cytisine dosing three times a day. The primary endpoint of the study will be the reduction in cigarette consumption over the treatment period. Currently, cytisine is approved in Central and Eastern Europe on a declining titration dose over a 25-day period.

According to Rick Stewart, chair and CEO of Achieve, “The successful outcome of our discussions with the FDA has provided us with clarity and direction to better inform our Phase 3 clinical development program and our efforts toward expanding Cytisine availability. Smoking is responsible for the deaths of nearly a half a million Americans every year and new treatment options are desperately needed to help those battling nicotine addiction.”

On June 26, ACHV stock registered a rise of ~34.2% as a result of positive study data from its drug metabolism, drug-drug interaction, and transporter studies of cytisine. For more information, read Achieve Life Sciences Stock Rose, Positive Data on Cytisine.

Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!